• Explore /
  • Poster
  • / <span>Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP).</span>

Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP).

Abstract Poster

Authors

Bruna Pellini

Bruna Pellini

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Bruna Pellini , Russell Madison , Merrida Childress , Shoshana T Miller , Jason H Cheng , Richard S.P. Huang , Michael Krainock , Pratyush Gupta , Wei Zou , David S. Shames , Solomon Moshkevich , Marcus Ballinger , Minetta C. Liu , Amanda Young , Minu K SRIVASTAVA , Geoffrey R. Oxnard , Mark A. Socinski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9075)

DOI

10.1200/JCO.2023.41.16_suppl.9075

Abstract #

9075

Poster Bd #

63

Abstract Disclosures

Similar Posters

First Author: Natalie I Vokes

First Author: Se-Hoon Lee

First Author: Antoine Italiano

First Author: Jillian Moran